Business Context and Reporting Period
This Form 8-K is filed by BioSig Technologies, Inc. (BSGM), not Streamex Corp., for the reporting period ending March 12, 2024. The filing addresses a critical delisting notice from The Nasdaq Capital Market. The Company is currently in a severe state of operational contraction, with Nasdaq staff determining it may no longer have an operating business and classifying it as a "public shell."
Key Financial and Operational Metrics
The filing does not provide specific revenue, profit, cash flow, or debt figures. However, it discloses the following critical operational metrics:
- Stock Price: Failed to meet the $1.00 minimum bid price requirement.
- Market Value: Failed to meet the $35 million minimum Market Value of Listed Securities requirement.
- Stockholders' Equity: Failed to meet the $5,000,000 minimum requirement, rendering the Company ineligible for a second 180-day cure period.
- Workforce: Reduced to one employee as of late February 2024.
- Board Composition: Reduced to one board member (Frederick Hrkac) as of late February 2024.
Material Changes Versus Prior Period
The Company has undergone drastic changes in leadership and operations between February 5, 2024, and March 12, 2024:
- Workforce Reduction: On February 5, 2024, the Company terminated 16 employees, including the Chief Operating Officer and Chief Commercial Officer.
- Executive Resignations: On February 21, 2024, the Chief Financial Officer resigned. On February 28, 2024, the Chief Executive Officer (Kennth Londoner) resigned.
- Board Turnover: On February 21, 2024, six of seven directors resigned, causing non-compliance with Nasdaq's majority independent board and committee requirements.
- Leadership Restructuring: Frederick Hrkac was reappointed to the board and named President and Principal Executive Officer.
Outlook, Risks, and Contingencies
Delisting Risk: Nasdaq staff has determined that the Company's continued listing is no longer warranted due to the "public shell" status and failure to meet multiple listing standards (bid price, market value, equity, and board composition).
Appeal Process: The Company submitted a request for a hearing on March 11, 2024, to appeal the delisting determination. The hearing before the Nasdaq Hearings Panel is scheduled for May 7, 2024.
Operational Viability: The filing highlights a significant risk that the Company no longer has an operating business, which is a primary basis for the delisting recommendation.
Investor Verification Checklist
- Verify the current status of the May 7, 2024, Nasdaq Hearings Panel decision.
- Confirm the Company's current cash position and ability to fund operations with only one employee.
- Check for any subsequent filings regarding the recruitment of new directors to restore board independence.
- Monitor stock trading status to determine if the stock has been suspended or delisted pending the hearing outcome.
- Review the Company's latest 10-K or 10-Q for detailed financial statements, as this 8-K contains no financial data.